Abstract
One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29years (range, 1 to 66years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45%±9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.
| Original language | English |
|---|---|
| Pages (from-to) | 1448-1450 |
| Number of pages | 3 |
| Journal | Biology of Blood and Marrow Transplantation |
| Volume | 20 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Acute myelogenous leukemia
- Hematopoietic stem cell transplantation
- Myelodysplastic syndrome
- Severe aplastic anemia
ASJC Scopus subject areas
- Transplantation
- Hematology
- Medicine(all)
Cite this
Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia : A report from the mds subcommittee of the chronic malignancies working party and the severe aplastic anemia working party of the european group for blood and marrow transplantation. / Hussein, Ayad Ahmed; Halkes, Constantijn M.; Socié, Gérard; Tichelli, André; von dem Borne, Peter A.; Schaap, Michel N P M; Foa, Robin; Ganser, Arnold; Dufour, Carlo; Bacigalupo, Andrea; Locasciulli, Anna; Aljurf, Mahmoud; Peters, Christina; Robin, Marie; van Biezen, Anja A.; Volin, Liisa; De Witte, Theo; Marsh, Judith; Passweg, Jakob R.; Kröger, Nicolas.
In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 9, 2014, p. 1448-1450.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Outcome of allogeneic stem cell transplantation for patients transformed to myelodysplastic syndrome or leukemia from severe aplastic anemia
T2 - A report from the mds subcommittee of the chronic malignancies working party and the severe aplastic anemia working party of the european group for blood and marrow transplantation
AU - Hussein, Ayad Ahmed
AU - Halkes, Constantijn M.
AU - Socié, Gérard
AU - Tichelli, André
AU - von dem Borne, Peter A.
AU - Schaap, Michel N P M
AU - Foa, Robin
AU - Ganser, Arnold
AU - Dufour, Carlo
AU - Bacigalupo, Andrea
AU - Locasciulli, Anna
AU - Aljurf, Mahmoud
AU - Peters, Christina
AU - Robin, Marie
AU - van Biezen, Anja A.
AU - Volin, Liisa
AU - De Witte, Theo
AU - Marsh, Judith
AU - Passweg, Jakob R.
AU - Kröger, Nicolas
PY - 2014
Y1 - 2014
N2 - One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29years (range, 1 to 66years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45%±9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.
AB - One hundred and forty patients who had undergone hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) transformation after treatment of severe aplastic anemia (SAA) were identified in the European Group for Blood and Marrow Transplantation (EBMT) database. The median age at HSCT was 29years (range, 1 to 66years). The transplant donor was related in 49% cases and unrelated in 51% cases. The 5-year probability of relapse was 17%, and that of nonrelapse mortality was 41%. The 5-year overall survival was 45%±9%, better for patients untreated and patients in remission compared with patients with refractory disease. Our data indicate that allogeneic HSCT leads to prolonged survival in close to one-half of the patients transforming to MDS or AML from SAA.
KW - Acute myelogenous leukemia
KW - Hematopoietic stem cell transplantation
KW - Myelodysplastic syndrome
KW - Severe aplastic anemia
UR - http://www.scopus.com/inward/record.url?scp=84905562090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905562090&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2014.05.028
DO - 10.1016/j.bbmt.2014.05.028
M3 - Article
C2 - 24910382
AN - SCOPUS:84905562090
VL - 20
SP - 1448
EP - 1450
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
SN - 1083-8791
IS - 9
ER -